Skip to Content

Vraylar Approval History

Vraylar (cariprazine) is a dopamine D3/D2 receptor partial agonist atypical antipsychotic for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia.

Development History and FDA Approval Process for Vraylar

Nov 13, 2017Approval Allergan Receives FDA Approval for Vraylar (cariprazine) in the Maintenance Treatment of Schizophrenia
Sep 17, 2015Approval FDA Approves Vraylar (cariprazine) for Schizophrenia and Bipolar Disorder
Jun 16, 2015Richter And Allergan Announce FDA Has Extended The Review Period For Cariprazine To September 2015
Jan 20, 2015Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia
Jan  6, 2015Actavis and Gedeon Richter Announce FDA Receipt of NDA Resubmission for Cariprazine
Nov 21, 2013Forest Laboratories and Gedeon Richter Receive Complete Response Letter for Cariprazine
Nov 28, 2012Forest Laboratories Submits New Drug Application for Cariprazine for the Treatment of Both Schizophrenia and Manic or Mixed Episodes Associated with Bipolar I Disorder

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.